【摘要】 目的研究辛伐他汀对脓毒症并发急性呼吸窘迫综合征(ARDS)患者外周血CD4+CD25+调节性T细胞(Treg)的影响。方法 65例脓毒症患者随机分为辛伐他汀治疗组(n=32)和对照组(n=33)。采集患者入选研究后的外周血行白细胞计数(WBC),C反应蛋白(CRP),降钙素原(PCT)检测来反映患者的感染程度,同时记录急性生理和慢性健康(APACHEⅡ)评分,流式细胞术(FCM)检测各组入选时、1、3、5、7、14 d的外周血CD4+CD25+Treg的水平。结果两组间的一般资料比较差异无统计学意义(P>0.05)。辛伐他汀治疗组的CD4+CD25+Treg在T淋巴细胞中的百分比逐渐下降,第14天两组间比较差异具有统计学意义[(7.32±1.86)%VS(10.01±5.63)%,t=2.568,P=0.013)]。结论辛伐他汀能改善脓毒症并发ARDS患者Treg过多的现象,起到调节免疫紊乱的功能。更多还原

【Abstract】 Objective To explore the influence of simvastatin on CD4+CD25+ regulatory T cell(Treg) in patients of sepsis complicated with acute respiratory distress syndrome(ARDS). Methods A total of 65 sepsis patients were randomly divided into simvastatin treatment group(n=32) and control group(n=33). Their peripheral blood white blood count(WBC), C-reactive protein(CRP) and procalcitonin(PCT) were collected and detected to show their infection degree. Their acute physiology score(APACHE Ⅱ) were recorded, and their peripheral blood CD4+CD25+ Treg levels were detected by flowcytometry(FCM) in admission time, and 1, 3, 5, 7, 14 d. ResultsThere was no statistically significant difference of general information between the two groups(P>0.05). The CD4+CD25+ Treg levels had decreasing percentage in T lymphocyte in the simvastatin treatment group. On 14 d, the difference between the two groups had statistical significance [(7.32±1.86)% VS(10.01±5.63)%, t=2.568, P=0.013)]. Conclusion Simvastatin can improve the Treg redundance in patients of sepsis complicated with ARDS, and it has regulation function for immunologic derangement.更多还原